Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.

Etheridge SL, Cosgrove ME, Sangkhae V, Corbo LM, Roh ME, Seeliger MA, Chan EL, Hitchcock IS.

Blood. 2014 Feb 13;123(7):1059-68. doi: 10.1182/blood-2012-12-473777. Epub 2013 Dec 31.

2.

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.

Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C, Leroy E, Harutyunyan AS, Abgrall JF, Favier R, Toussaint A, Solary E, Kralovics R, Constantinescu SN, Najman A, Vainchenker W, Plo I, Bellanné-Chantelot C.

Blood. 2014 Feb 27;123(9):1372-83. doi: 10.1182/blood-2013-05-504555. Epub 2014 Jan 7.

3.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
4.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
5.

JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Tefferi A.

Cancer J. 2007 Nov-Dec;13(6):366-71. Review.

PMID:
18032973
6.

New advances in the pathogenesis and therapy of essential thrombocythemia.

Levine RL, Heaney M.

Hematology Am Soc Hematol Educ Program. 2008:76-82. doi: 10.1182/asheducation-2008.1.76. Review.

PMID:
19074062
7.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
8.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.

9.

[Detection of the JAK2 gene mutation in familial myeloproliferative neoplasm and its clinical significance].

Zhang YM, Hao LX, Wei Q, Wei YQ, Huang F, Zhang Y, Yin CX, Feng R.

Zhonghua Xue Ye Xue Za Zhi. 2012 Feb;33(2):103-7. Chinese.

PMID:
22730657
10.

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.

Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.

FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.

PMID:
22051730
11.

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.

12.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22. Review.

PMID:
18496562
13.

Essential Thrombocythemia Associated With Germline JAK2 G571S Variant and Somatic CALR Type 1 Mutation.

Panovska-Stavridis I, Eftimov A, Ivanovski M, Pivkova-Veljanovska A, Cevreska L, Hermouet S, Dimovski AJ.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):e55-7. doi: 10.1016/j.clml.2016.02.039. Epub 2016 Feb 27. No abstract available.

PMID:
27009537
14.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568
15.

Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.

Medeiros BC, Zhang T, Lipton JH, Kamel-Reid S.

Am J Hematol. 2007 Apr;82(4):293-4.

16.

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.

Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative.

PLoS One. 2013;8(1):e54826. doi: 10.1371/journal.pone.0054826. Epub 2013 Jan 31.

17.

[Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].

Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.

Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):510-4. Chinese.

PMID:
19950698
18.

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Geyer HL, Mesa RA.

Expert Opin Investig Drugs. 2012 Dec;21(12):1755-74. doi: 10.1517/13543784.2012.721352. Epub 2012 Sep 19. Review.

PMID:
22991927
19.

Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.

Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V.

Exp Hematol. 2009 Oct;37(10):1194-200. doi: 10.1016/j.exphem.2009.07.003. Epub 2009 Jul 15.

PMID:
19615425
20.

Impact of isolated germline JAK2V617I mutation on human hematopoiesis.

Mead AJ, Chowdhury O, Pecquet C, Dusa A, Woll P, Atkinson D, Burns A, Score J, Rugless M, Clifford R, Moule S, Bienz N, Vyas P, Cross N, Gale RE, Henderson S, Constantinescu SN, Schuh A, Jacobsen SE.

Blood. 2013 May 16;121(20):4156-65. doi: 10.1182/blood-2012-05-430926. Epub 2013 Mar 27.

Supplemental Content

Support Center